sarsassoci
coronaviru
identifi
etiolog
agent
sever
acut
respiratori
syndrom
larg
viru
pool
identifi
wild
anim
viru
gener
drug
resist
fast
mutagenesi
escap
antivir
treatment
sirna
target
differ
gene
would
altern
overcom
drug
resist
report
effect
sirna
target
structur
gene
ie
spike
envelop
membran
nucleocapsid
antivir
kinet
also
show
synergist
effect
two
sirna
target
differ
function
gene
low
dose
find
may
pave
way
develop
cost
effect
sirna
agent
antivir
therapi
futur
sever
acut
respiratori
syndrom
sar
spread
thirti
countri
infect
individu
kill
live
around
world
wwwwhointcsrsar
en
isol
sar
case
report
taiwan
late
china
earli
novel
coronaviru
sarsassoci
coronaviru
scov
identifi
agent
sar
scov
produc
similar
type
pneumonia
monkey
anim
scovlik
viral
pool
larg
number
wild
anim
like
scov
origin
wild
anim
later
transmit
human
sar
transmit
airway
nasal
passag
urin
water
domest
pet
identif
scovlik
viru
beast
bat
indic
outbreak
diseas
difficult
rule
vaccin
specif
effect
antivir
method
yet
develop
treat
diseas
scov
larg
envelop
positivestrand
rna
viru
genom
compos
nucleotid
organ
genom
typic
coronavirus
follow
characterist
gene
order
replicas
rep
spike
envelop
e
membran
nucleocapsid
n
fig
nonstructur
rep
gene
compris
genom
encod
two
polyprotein
encod
undergo
cotransl
proteolyt
process
rep
gene
product
translat
genom
rna
play
key
role
viral
replic
viral
gene
transcript
structur
protein
translat
subgenom
mrna
synthes
discontinu
transcript
process
spike
glycoprotein
shown
viral
ligand
play
critic
role
viru
bind
receptor
viral
entri
host
cell
base
peptid
protect
studi
show
spike
protein
good
target
prevent
viral
infect
nucleocapsid
protein
shown
play
role
viral
genom
packag
transcript
regul
viral
gene
intracellular
signal
envelop
protein
membran
protein
involv
viral
packag
viral
secret
viruscel
interact
small
interf
rna
sirna
short
hairpin
rna
shrna
potent
agent
silenc
gene
express
viral
infect
replic
sequencespecif
manner
replicas
long
favorit
target
antivir
drug
develop
first
group
demonstr
sirna
target
rep
gene
potent
inhibit
scov
infect
replic
howev
recent
studi
reveal
virus
could
easili
escap
sirna
target
fast
mutagenesi
therefor
identif
multipl
effect
sirna
target
differ
site
function
gene
scov
would
altern
treatment
possibl
sar
outbreak
futur
sirna
design
synthesi
screen
sirna
ration
design
accord
new
strategi
describ
recent
candid
sirna
score
six
select
subject
blast
search
genbank
ensur
uniqu
scov
genom
sequenc
three
sirna
target
gene
design
chemic
synthes
proligo
biotech
ltd
pari
franc
antivir
effect
detect
cytopath
effect
cpe
assay
sirna
markedli
inhibit
cpe
chosen
studi
sensestrand
sequenc
sirna
cacugauuccguucgagauc
sarsi
cguuucggaagaaacagguac
sarsi
caagccucuucucgcuccuc
sarsin
ugcuugcugcugucuacag
guggcuuagcuacuucguug
sequenc
correspond
nucleotid
stain
access
number
respect
fig
sarsir
potent
sirna
target
rep
gene
gcacuugucuaccuugaug
ref
use
posit
control
studi
sirna
target
luciferas
mrna
use
sarsunrel
sirna
control
sirna
label
fluoresc
end
sens
strand
fetal
rhesu
kidney
cell
cultur
maintain
mem
medium
fetal
bovin
serum
fb
invitrogen
around
cell
set
well
dish
viral
infect
replic
assay
cell
transfect
either
without
neg
control
sirna
standard
concentr
nm
use
oligofectmin
invitrogen
ca
accord
manufactur
instruct
six
hour
transfect
cultur
medium
remov
cell
wash
twice
pb
scov
infect
one
hundr
microlit
sarsassoci
coronaviru
dilut
mem
fb
ad
transfect
cell
multipl
infect
cytopath
effect
cpe
observ
record
phasecontrast
microscop
h
postinfect
experi
perform
triplic
repeat
least
three
time
total
intracellular
rna
isol
use
rneasi
mini
kit
qiagen
germani
accord
manufactur
instruct
reversetranscript
experi
perform
use
thermoscript
rtpcr
system
invitrogen
ca
realtim
pcr
perform
use
forward
primer
strain
nt
revers
primer
nt
fluoresc
probe
fam
ctaatgctgtagtgaaaatgccatgtcctgc
trma
nt
primer
probe
bind
region
replicas
permit
us
measur
viral
genom
rna
copi
two
microlit
rt
product
templat
use
reaction
forward
revers
primer
final
concentr
nm
fluoresc
probe
final
concentr
nm
mix
master
mix
abi
usa
realtim
quantif
carri
use
sequenc
detect
system
pcr
condit
min
min
cycl
sec
min
condit
medium
infect
cell
dilut
serial
mem
fb
use
infect
cell
accord
standard
protocol
briefli
cell
set
dish
sixteen
hour
infect
seventytwo
hour
postinfect
cpe
observ
record
phasecontrast
microscopi
h
postinfect
infecti
viral
titer
calcul
viru
would
easili
escap
antivir
treatment
drug
target
singl
site
gene
via
fast
mutagenesi
larg
scovlik
viru
pool
number
wild
anim
would
use
develop
multipl
costeffect
specif
agent
clinic
use
futur
appar
develop
sirna
multipl
gene
would
altern
base
newli
develop
ration
design
protocol
systemat
design
synthes
multipl
sirna
target
structur
gene
e
n
detect
antivir
activ
cpe
assay
describ
select
effect
sirna
studi
fig
monkey
kidney
cell
use
scov
infect
replic
assay
cell
set
dish
transfect
without
sirna
transfect
effici
monitor
fluoresc
microscopi
appear
almost
cell
transfect
cell
infect
scov
h
transfect
cpe
monitor
phasecontrast
microscopi
record
cpe
h
postinfect
use
phasecontrast
microscopi
noninfect
cell
healthi
show
clear
round
shape
fig
panel
infect
cell
display
longer
shape
cell
even
float
away
fig
panel
ii
toxic
cpe
discov
cell
transfect
sirna
target
unrel
luciferas
mrna
fig
panel
iii
scov
rna
without
viru
infect
data
shown
cytopath
effect
appear
cell
transfect
without
infect
scov
fig
panel
ii
iv
effect
sirna
target
replicas
fig
panel
v
cell
transfect
effect
sirna
target
structur
gene
sarsi
sarsi
sarsin
fig
panel
vix
protect
cpe
character
antivir
effect
individu
effect
sirna
determin
copi
number
intracellular
viral
genom
rna
use
realtim
rtpcr
assay
transfect
cell
sirna
infect
scov
hour
transfect
isol
total
cellular
rna
infect
cell
h
postinfect
quantifi
viral
genom
copi
realtim
pcr
found
intracellular
viral
rna
level
reduc
sarsi
sarsi
sarsin
compar
control
standard
concentr
nm
fig
result
indic
sirna
potent
inhibit
scov
rna
replic
interest
us
understand
viral
kinet
sirna
target
scov
knowledg
one
address
viral
kinet
effect
sirna
scov
intracellular
rna
level
cours
key
paramet
monitor
kinet
viral
replic
therefor
carri
quantit
rtpcr
experi
determin
scov
genom
rna
copi
infect
cell
differ
time
point
infect
cell
becam
sever
sick
h
postinfect
therefor
measur
intracellular
viral
rna
copi
experi
perform
triplic
repeat
least
three
time
detect
reveal
sirna
reduc
viral
replic
effect
student
test
p
valu
mean
se
shown
typic
experi
valu
sarsir
sarsi
sarsi
sarsin
time
point
h
time
point
h
isol
total
rna
infect
cell
measur
viral
genom
rna
copi
quantit
rtpcr
found
intracellular
viral
rna
copi
almost
regardless
transfect
without
sirna
indic
transfect
sirna
prevent
viru
entri
therefor
defin
rel
copi
number
control
sampl
intracellular
viral
genom
rna
copi
increas
time
within
h
increas
anoth
time
follow
h
result
viral
genom
rna
copi
amplifi
cell
first
h
howev
viral
genom
rna
copi
increas
fold
either
time
point
h
time
point
h
tabl
result
suggest
viral
reproduct
display
two
phase
cell
ie
fast
replic
phase
h
viral
packag
secret
phase
h
follow
h
viral
genom
rna
level
reduc
test
sirna
tabl
next
h
h
rna
copi
significantli
reduc
sarsir
strong
inhibit
maintain
h
viral
genom
rna
copi
almost
unchang
h
posttransfect
eighteen
hour
postinfect
viral
genom
rna
copi
increas
rapidli
inhibit
drop
time
point
h
tabl
sirna
target
gene
sarsi
fivefold
inhibit
observ
time
point
h
inhibit
observ
time
point
h
sirna
target
structur
gene
viral
genom
rna
copi
reduc
time
point
fig
remain
determin
whether
reduc
rna
level
sirna
target
differ
region
similar
impact
infecti
viral
titer
ie
viral
reproduct
live
sarsassoci
coronaviru
contain
intact
viral
genom
rna
function
viral
protein
factor
effici
correct
viral
rna
replic
viral
packag
secret
determin
infecti
viral
titer
elucid
effect
sirna
viral
titer
perform
viru
infect
assay
experi
h
postinfect
remov
media
wash
cell
twice
pb
contain
mm
edta
fresh
mem
medium
contain
fb
ad
cell
incub
h
viral
titer
condit
media
measur
assay
found
nm
sirna
markedli
reduc
infecti
virus
secret
accumul
cultur
media
data
shown
determin
whether
scov
inhibit
sirna
dosedepend
manner
differ
amount
scovspecif
sirna
transfect
cell
viral
infec
dose
shown
satur
sirna
concentr
combin
sirna
gene
would
increas
antivir
activ
interest
question
whether
synergist
antivir
effect
would
achiev
combin
sirna
target
differ
gene
lower
dose
would
offer
opportun
develop
costeffect
specif
agent
combat
sar
outbreak
drug
resist
futur
answer
question
first
reduc
concentr
sirna
nm
transfect
mixtur
without
carrier
sirna
observ
antivir
effect
assay
lower
inhibitori
effect
observ
data
shown
concentr
decreas
note
viral
genom
rna
copi
number
h
postinfect
defin
nm
viral
titer
reduc
sasrir
sarsi
sarsi
respect
fig
intrigu
whether
antiscov
effect
could
restor
two
sirna
target
differ
gene
lower
dose
would
overcom
major
cost
barrier
clinic
set
test
possibl
transfect
either
singl
sirna
two
sirna
cell
investig
antisar
activ
experi
total
dosag
sirna
nm
use
transfect
regardless
one
two
sirna
measur
viral
titer
condit
media
assay
h
postinfect
experi
use
combin
two
sirna
inhibit
significantli
increas
compar
control
viral
titer
reduc
sarsir
sarsis
combin
combin
combin
respect
sarsassoci
coronaviru
novel
identifi
rna
viru
pose
sever
threat
human
health
larg
scovlik
viru
pool
number
anim
speci
current
knowledg
scov
limit
paper
report
antivir
effect
genom
rna
kinet
effect
sirna
target
differ
function
gene
synergist
antivir
effect
low
dose
two
sirna
differ
gene
use
combin
find
may
combat
scov
resist
singl
sirna
via
fast
mutagenesi
pave
way
develop
costeffect
sirna
agent
antisar
treatment
specif
sirna
target
scov
genom
rna
would
lead
viral
rna
cleavag
host
cell
previous
identifi
effect
sirna
target
rep
gene
markedli
reduc
intracellular
viral
genom
rna
level
studi
show
sirna
target
sem
structur
gene
also
inhibit
viral
rna
accumul
host
cell
lower
effici
fig
exhibit
almost
inhibitori
activ
viral
reproduct
fig
may
sever
reason
phenomenon
first
viral
genom
rna
immedi
translat
viral
protein
undergo
fast
rna
replic
phase
measur
timepoint
experi
enter
cell
replicas
encod
viral
genom
rna
directli
respons
viral
rna
synthesi
therefor
sirna
target
replicas
region
directli
reduc
replicas
secondli
region
viral
genom
rna
encod
sever
subgenom
mrna
subgenom
mrna
abund
host
cell
may
reduc
target
effici
prolong
time
cleavag
viral
genom
rna
final
activ
transcript
andor
translat
region
viral
genom
rna
may
block
sirna
target
site
howev
structur
gene
product
directli
contribut
impact
viral
packag
infecti
activ
accumul
infecti
virus
reli
replic
correct
effect
packag
therefor
could
display
similar
inhibitori
activ
product
infecti
virion
sarsir
satur
concentr
media
kinet
studi
show
rna
replic
took
place
two
phase
rapid
replic
phase
h
slow
replic
phase
h
first
h
viral
genom
rna
increas
near
howev
viral
genom
rna
increas
next
h
tabl
viral
genom
rna
replic
potent
inhibit
first
six
hour
postinfect
cell
transfect
specif
sirna
target
function
gene
unknown
reason
fig
viral
rna
accumul
almost
complet
inhibit
cell
transfect
sarsir
h
postinfect
viral
rna
copi
also
increasingli
multipli
cell
transfect
specif
sirna
h
h
postinfect
copi
viral
genom
rna
increas
faster
cell
h
postinfect
case
sarsir
result
suggest
transfect
sirna
cell
rel
short
halflif
therefor
sustain
express
shrna
via
viral
vector
eg
adenovirusbas
shortterm
express
vector
would
offer
altern
antisar
therapi
variou
combin
sirna
target
differ
gene
may
produc
synergist
antiscov
effect
differ
gene
play
distinguish
function
viral
life
cycl
observ
obviou
synergist
antiscov
effect
two
three
effect
sirna
target
replicas
region
studi
show
specif
sirna
low
concentr
highli
concentr
carrier
sirna
total
sirna
maintain
nm
fig
exhibit
potent
antiscov
activ
know
dna
rna
carrier
reagent
would
increas
transfect
effici
extend
life
transfect
dna
rna
cell
therefor
first
investig
whether
sirna
would
display
similar
antivir
activ
lower
dose
without
carrier
sirna
found
singl
sirna
low
concentr
nm
without
carrier
sirna
significantli
reduc
antivir
activ
combin
two
sirna
target
differ
function
gene
display
synergist
antivir
activ
fig
consid
sarsir
could
repress
viral
reproduct
nm
concentr
combin
sirna
two
differ
gene
exhibit
reduct
combin
effect
result
suggest
combin
effect
sirna
target
differ
gene
could
use
clinic
applic
reduc
toxic
lower
cost
result
demonstr
sirna
target
functiondistinguish
structur
gene
achiev
vari
degre
success
inhibit
viral
genom
rna
accumul
host
cell
reduc
viral
titer
almost
level
effect
sirna
target
replicas
gene
addit
also
show
sirna
target
rep
e
gene
low
concentr
display
synergist
activ
restor
even
display
better
antivir
activ
singl
sirna
alon
satur
concentr
previou
studi
show
spike
protein
would
good
target
antisar
drug
develop
sirna
exhibit
synergist
antivir
effect
chemic
drug
take
togeth
suggest
replicas
spike
protein
envelop
protein
membran
protein
would
serv
target
sirnasshrna
deliv
vector
eg
adenovir
vector
inhibit
viral
replic
infect
